The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis (UC ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis. Twenty-four ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Tremfya met its primary and major secondary endpoints in the Phase 3b study, showing reduced symptoms and structural damage. Tremfya-treated patients had significantly less structural damage ...

Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab) has met the primary and major secondary endpoints in a Phase 3b APEX study for treating active ...

Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting the antibody-based drug’s efficacy as a first-line option for ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...